Literature DB >> 25512383

Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.

Ranran Wang1, Jianxin You2.   

Abstract

NUT midline carcinoma (NMC) is a rare but highly aggressive cancer typically caused by the translocation t(15;19), which results in the formation of the BRD4-NUT fusion oncoprotein. Previous studies have demonstrated that fusion of the NUT protein with the double bromodomains of BRD4 may significantly alter the cellular gene expression profile to contribute to NMC tumorigenesis. However, the mechanistic details of this BRD4-NUT function remain poorly understood. In this study, we examined the NUT function in transcriptional regulation by targeting it to a LacO transgene array integrated in U2OS 2-6-3 cells, which allow us to visualize how NUT alters the in situ gene transcription dynamic. Using this system, we demonstrated that the NUT protein tethered to the LacO locus recruits p300/CREB-binding protein (CBP), induces histone hyperacetylation, and enriches BRD4 to the transgene array chromatin foci. We also discovered that, in BRD4-NUT expressed in NMC cells, the NUT moiety of the fusion protein anchored to chromatin by the double bromodomains also stimulates histone hyperacetylation, which causes BRD4 to bind tighter to chromatin. Consequently, multiple BRD4-interacting factors are recruited to the NUT-associated chromatin locus to activate in situ transgene expression. This gene transcription function was repressed by either expression of a dominant negative inhibitor of the p300-NUT interaction or treatment with (+)-JQ1, which dissociates BRD4 from the LacO chromatin locus. Our data support a model in which BRD4-NUT-stimulated histone hyperacetylation recruits additional BRD4 and interacting partners to support transcriptional activation, which underlies the BRD4-NUT oncogenic mechanism in NMC.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Acetyltransferase; BRD4-NUT; Bromodomain-containing Protein 4 (BRD4); E1A Binding Protein p300 (P300); NUT Midline Carcinoma; Transcription Elongation Factor; Transcription Factor; Transcriptional Activation

Mesh:

Substances:

Year:  2014        PMID: 25512383      PMCID: PMC4317035          DOI: 10.1074/jbc.M114.600759

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Targeting MYC dependence in cancer by inhibiting BET bromodomains.

Authors:  Jennifer A Mertz; Andrew R Conery; Barbara M Bryant; Peter Sandy; Srividya Balasubramanian; Deanna A Mele; Louise Bergeron; Robert J Sims
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

2.  Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains.

Authors:  Nicolas Reynoird; Brian E Schwartz; Manuela Delvecchio; Karin Sadoul; David Meyers; Chandrani Mukherjee; Cécile Caron; Hiroshi Kimura; Sophie Rousseaux; Philip A Cole; Daniel Panne; Christopher A French; Saadi Khochbin
Journal:  EMBO J       Date:  2010-07-30       Impact factor: 11.598

3.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

4.  Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.

Authors:  Junpeng Yan; Jason Diaz; Jing Jiao; Ranran Wang; Jianxin You
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

5.  The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3.

Authors:  Shaila Rahman; Mathew E Sowa; Matthias Ottinger; Jennifer A Smith; Yang Shi; J Wade Harper; Peter M Howley
Journal:  Mol Cell Biol       Date:  2011-05-09       Impact factor: 4.272

Review 6.  NUT midline carcinoma.

Authors:  Christopher Alexander French
Journal:  Cancer Genet Cytogenet       Date:  2010-11

7.  Abrogation of the Brd4-positive transcription elongation factor B complex by papillomavirus E2 protein contributes to viral oncogene repression.

Authors:  Junpeng Yan; Qing Li; Sam Lievens; Jan Tavernier; Jianxin You
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

8.  NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.

Authors:  Christopher A French; Shaila Rahman; Erica M Walsh; Simone Kühnle; Adlai R Grayson; Madeleine E Lemieux; Noam Grunfeld; Brian P Rubin; Cristina R Antonescu; Songlin Zhang; Rajkumar Venkatramani; Paola Dal Cin; Peter M Howley
Journal:  Cancer Discov       Date:  2014-05-29       Impact factor: 39.397

9.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Authors:  Johannes Zuber; Junwei Shi; Eric Wang; Amy R Rappaport; Harald Herrmann; Edward A Sison; Daniel Magoon; Jun Qi; Katharina Blatt; Mark Wunderlich; Meredith J Taylor; Christopher Johns; Agustin Chicas; James C Mulloy; Scott C Kogan; Patrick Brown; Peter Valent; James E Bradner; Scott W Lowe; Christopher R Vakoc
Journal:  Nature       Date:  2011-08-03       Impact factor: 49.962

10.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

View more
  27 in total

1.  Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma.

Authors:  Ranran Wang; Xing-Jun Cao; Katarzyna Kulej; Wei Liu; Tongcui Ma; Margo MacDonald; Cheng-Ming Chiang; Benjamin A Garcia; Jianxin You
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

2.  "Z4" Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism.

Authors:  Hitoshi Shiota; Janine E Elya; Artyom A Alekseyenko; Pauline M Chou; Shelby A Gorman; Olena Barbash; Kelly Becht; Kristina Danga; Mitzi I Kuroda; Valentina Nardi; Christopher A French
Journal:  Mol Cancer Res       Date:  2018-08-23       Impact factor: 5.852

Review 3.  Targeting Cancer Cells with BET Bromodomain Inhibitors.

Authors:  Yali Xu; Christopher R Vakoc
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

Review 4.  Erythropoiesis provides a BRD's eye view of BET protein function.

Authors:  Aaron J Stonestrom; Sarah C Hsu; Michael T Werner; Gerd A Blobel
Journal:  Drug Discov Today Technol       Date:  2016-07-20

Review 5.  Bromodomain 4: a cellular Swiss army knife.

Authors:  Ballachanda N Devaiah; Anne Gegonne; Dinah S Singer
Journal:  J Leukoc Biol       Date:  2016-07-22       Impact factor: 4.962

Review 6.  Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.

Authors:  Gerard L Brien; Daria G Valerio; Scott A Armstrong
Journal:  Cancer Cell       Date:  2016-04-11       Impact factor: 31.743

7.  Tandem Histone-Binding Domains Enhance the Activity of a Synthetic Chromatin Effector.

Authors:  Stefan J Tekel; Daniel A Vargas; Lusheng Song; Joshua LaBaer; Michael R Caplan; Karmella A Haynes
Journal:  ACS Synth Biol       Date:  2018-02-23       Impact factor: 5.110

8.  Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma.

Authors:  Michela Maur; Angela Toss; Massimo Dominici; Antonio Frassoldati; Paolo Corradini; Antonio Maiorana; Annalisa Fontana; Pierfranco Conte
Journal:  Am J Case Rep       Date:  2015-07-03

9.  Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.

Authors:  Hitoshi Shiota; Artyom A Alekseyenko; Zhipeng A Wang; Ivona Filic; Tatiana M Knox; Nhi M Luong; Yeying Huang; David A Scott; Kristen L Jones; Prafulla C Gokhale; Madeleine E Lemieux; Philip A Cole; Mitzi I Kuroda; Christopher A French
Journal:  Mol Cancer Res       Date:  2021-07-20       Impact factor: 5.852

10.  The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains.

Authors:  Artyom A Alekseyenko; Erica M Walsh; Xin Wang; Adlai R Grayson; Peter T Hsi; Peter V Kharchenko; Mitzi I Kuroda; Christopher A French
Journal:  Genes Dev       Date:  2015-07-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.